Related Experiment Videos
Reactogenicity and immunogenicity of a double-strength acellular pertussis vaccine
D A Blumberg1, P C Chatfield, J D Cherry
1Department of Pediatrics, UCLA School of Medicine.
Insights
This study found that a double-strength acellular pertussis vaccine was safe and effective in children. High doses of filamentous haemagglutinin did not increase side effects, suggesting it
Area of Science:
- Immunology
- Vaccinology
Background:
- Pertussis (whooping cough) remains a public health concern.
- Acellular pertussis vaccines (aP) are widely used but can vary in composition and reactogenicity.
- Filamentous haemagglutinin (FHA) is a key component of many aP vaccines.
Purpose of the Study:
- To evaluate the safety (reactogenicity) and efficacy (immunogenicity) of a novel double-strength aP vaccine in children.
- To assess the role of a high dose of FHA in vaccine reactogenicity.
Main Methods:
- A double-strength aP vaccine was administered to 16 children aged 4-6 years.
- The vaccine contained specific quantities of toxoided lymphocytosis-promoting factor, FHA, agglutinogens, and the 69 kDa protein.
- Reactogenicity was monitored through reported side effects.
- Immunogenicity was assessed by measuring antibody levels to vaccine components.
Main Results:
- The double-strength aP vaccine demonstrated excellent tolerability with minimal reported side effects.
- Significant increases in antibodies against all pertussis vaccine components were observed post-vaccination.
- The high FHA content (70 micrograms/dose) did not correlate with increased reactogenicity.
Conclusions:
- The double-strength acellular pertussis vaccine is safe and immunogenic in 4-6-year-old children.
- Filamentous haemagglutinin, even at high doses, does not appear to be a primary driver of vaccine reactogenicity.
- This vaccine formulation shows promise for effective pertussis immunization.
Abstract:
The reactogenicity and immunogenicity of a double-strength acellular pertussis vaccine were evaluated after administration to 16 4-6-year-old children. The vaccine contained toxoided lymphocytosis-promoting factor (6.0 micrograms/dose), filamentous haemagglutinin (70 micrograms/dose), agglutinogens (1.4 micrograms/dose) and the 69 kDa protein (approximately 8.0 micrograms/dose). The vaccine was extremely well tolerated with few minor side effects following immunization. Significant increases in antibodies to all pertussis vaccine components were noted. In summary, this double-strength acellular pertussis vaccine, containing a very high dose of filamentous haemagglutinin, had minimal reactogenicity and was immunogenic. These findings, as well as other studies with this vaccine, indicate that filamentous haemagglutinin is not a major determinant of vaccine reactogenicity.